Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
1-1-2020

Radiation and checkpoint inhibitor immunotherapy lead to long
term disease control in a metastatic RCC patient with brain
metastases
Maria Levitin
Barbara Ann Karmanos Cancer Institute

Joel Ofori
Washington University School of Medicine in St. Louis

Woo Jae Shin
Washington University School of Medicine in St. Louis

Jiayi Huang
Washington University School of Medicine in St. Louis

Mackenzie Daly
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Levitin, Maria; Ofori, Joel; Shin, Woo Jae; Huang, Jiayi; Daly, Mackenzie; Cao, Dengfeng; and Pachynski,
Russell, ,"Radiation and checkpoint inhibitor immunotherapy lead to long term disease control in a
metastatic RCC patient with brain metastases." Frontiers in Oncology. 10,. . (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9692

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Maria Levitin, Joel Ofori, Woo Jae Shin, Jiayi Huang, Mackenzie Daly, Dengfeng Cao, and Russell
Pachynski

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/9692

CASE REPORT
published: 23 September 2020
doi: 10.3389/fonc.2020.566070

Radiation and Checkpoint Inhibitor
Immunotherapy Lead to Long Term
Disease Control in a Metastatic RCC
patient With Brain Metastases
Maria Levitin 1 , Joel Ofori 2 , Woo Jae Shin 3 , Jiayi Huang 4 , Mackenzie Daly 4 ,
Dengfeng Cao 5 and Russell Pachynski 3,6*
1
Barbara Ann Karmanos Cancer Institute, Detroit, MI, United States, 2 Washington University School of Medicine, St. Louis,
MO, United States, 3 Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis,
MO, United States, 4 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO,
United States, 5 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO,
United States, 6 Bursky Center for Human Immunology and Immunotherapy Programs (CHiiPs), Washington University
School of Medicine, St. Louis, MO, United States

Edited by:
Ugo De Giorgi,
Romagnolo Scientific Institute for the
Study and Treatment of Tumors
(IRCCS), Italy
Reviewed by:
Jaleh Fallah,
Cleveland Clinic, United States
Takeshi Yuasa,
Japanese Foundation for Cancer
Research, Japan
*Correspondence:
Russell Pachynski
rkpachynski@wustl.edu
Specialty section:
This article was submitted to
Genitourinary Oncology,
a section of the journal
Frontiers in Oncology
Received: 27 May 2020
Accepted: 13 August 2020
Published: 23 September 2020
Citation:
Levitin M, Ofori J, Shin WJ, Huang J,
Daly M, Cao D and Pachynski R
(2020) Radiation and Checkpoint
Inhibitor Immunotherapy Lead to Long
Term Disease Control in a Metastatic
RCC patient With Brain Metastases.
Front. Oncol. 10:566070.
doi: 10.3389/fonc.2020.566070

Frontiers in Oncology | www.frontiersin.org

Renal cell carcinoma (RCC) comprises 4.2% of all new cancer cases in the United States
and 30% of cases are metastatic (mRCC) at diagnosis. Brain metastatic RCC historically
has poor prognosis, but the development of immune checkpoint inhibitors has
revolutionized their care and may be successfully combined with SBRT to improve
prognosis. Here, we present a case of a patient with mRCC who had brain metastases
treated with concurrent immune checkpoint inhibitors and SBRT. He continues to survive
with good functional status years following his initial diagnosis. We discuss the relevant
history regarding treatment approach in patients with brain metastatic RCC, ongoing
trials focusing on the combination of immunotherapy and radiation, and the potential
and promise of the abscopal effect.
Keywords: renal cell carcinoma (RCC), brain metastases (BMs), immunotherapy, SBRT (stereotactic body radiation
therapy), abscopal

INTRODUCTION
Renal cell carcinoma (RCC) comprises 4.2% of all new cancer cases in the United States,
with an estimated 73,820 diagnoses in 2019 (1, 2). Thirty percent of cases are metastatic at
the time of diagnosis (3) and the incidence of brain metastasis over the course of 5 years
is 9.8% (4). Prognosis without treatment is poor, with median survival of about 3 to 4
months (5). Prior to the use of targeted agents, mRCC was treated with interferon and the
possible addition of surgery, whole brain radiotherapy, or radiosurgery for brain metastases.
The prognosis for patients with brain metastases stagnated at around 3–7 months (5, 6). The
development of targeted agents represented the first appreciable increase in life expectancy
to a median overall survival (OS) of 9.2 months (7, 8). The management of mRCC has
been revolutionized with the development of immune checkpoint inhibitors. Nivolumab is an
immunoglobulin (Ig) G4 antibody against human programmed death (PD) 1 that blocks the
interaction between PD-1 and its ligands PD-L1 and PD-L2. This helps limit the downregulation
of immunostimulatory cytokines and exhaustion that occur during T cell receptor stimulation,
mediated in part by the PD-1 receptor (9). The CheckMate 025 trial was an open label,
randomized phase 3 study of patients with mRCC previously treated with antiangiogenic
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in the left posterior parietal lesion. The patient underwent
surgical evacuation of the hematoma in November 2016 without
local therapy for the metastases. All neurologic deficits resolved,
and the patient was asymptomatic from his disease.
Brain imaging in March 2017 discovered two new metastatic
lesions measuring 6 mm in the left temporal lobe and 3 mm
in the right frontal lobe. Due to his excellent functional status,
the patient declined further radiosurgery in favor of continued
immunotherapy with close monitoring. His next brain MRI
in May 2017 revealed complete resolution of the two lesions
(Figure 2). Therapy with nivolumab was generally well-tolerated,
however, the patient did develop a grade 3 immune-mediated
rash (confirmed by biopsy) in July 2017 after ∼1 year on
nivolumab therapy. He was treated with a prolonged steroid
course, with eventual complete resolution of his rash.
In January 2018, after extensive discussion regarding the
potential risks and benefits, he was re-started on nivolumab.
The patient demonstrated stable disease with interval decrease
in the size of the primary lesion. However, in consultation with
Radiation Oncology, the decision was made to administer SBRT
to the primary site. He was treated to 40 Gy in five fractions
in March 2018. Nivolumab was continued until May 2018 but
held at that time due to fatigue. The patient completed a total
of 34 cycles of nivolumab in May 2018 and has not received
additional therapy since then. The patient’s most recent imaging
in May 2020 showed a stable 4.6 cm left renal lesion with
stable small pulmonary lesions and no other evidence of disease
(Figures 2C,D).

therapy which showed that second line treatment with nivolumab
improved OS to 25.0 months compared to 19.6 months with the
mTOR inhibitor everolimus (10). This led to the FDA approval
of nivolumab in RCC and established it as the standard of care
for mRCC in the second line setting. Several other checkpoint
inhibitors including ipilimumab (anti-CTLA4; in combination
with nivolumab), pembrolizumab (anti-PD1; in combination
with axitinib), and avelumab (anti-PD-L1; in combination with
axitinib) have been approved for the treatment of advanced RCC,
with several others currently under investigation (11).
RCC has traditionally considered radioresistant (12). This is
based on trials from the 1970’s and 80’s that utilized outdated
radiation techniques and in vitro data describing methods
of RCC resistance to radiation (13, 14). Newer data suggest
that modern stereotactic ablative radiotherapy can bypass the
resistance mechanism and can be an effective therapy both
in the primary setting and in treating metastatic disease (14).
More recently, there has been interest in interactions between
radiation and immunotherapy. Here, we present a patient
with mRCC with brain metastases who received checkpoint
inhibitors and radiotherapy, with near complete response.
We highlight relevant aspects of the case and discuss the
current status of combining radiotherapy and immunotherapy
in mRCC.

Case Vignette
An 83-year-old male presented in March 2016 with progressive
shortness of breath (Figure 1). CT angiogram (CTA) revealed
multiple bilateral lung nodules, pleural effusion, and a large left
kidney mass measuring 9.1 × 7.5 cm concerning for malignancy.
Biopsy of a right pleural based mass demonstrated RCC, clear
cell histology. Bone scan and plain-radiograph showed a single
site of bone involvement, with a lytic lesion measuring 3.4 ×
2.3 cm in the left femoral diaphysis. The patient was started
on systemic therapy with pazopanib until he developed liver
toxicity 2 months later. Shortly following cessation of the
medication in June 2016, he again complained of dyspnea and
new right foot drop. Imaging showed progression of metastatic
disease with bilateral increase in size of pulmonary nodules,
mediastinal lymphadenopathy, an additional osseous lesion in
the pelvis, and growth of the primary lesion (Figure 2B). MRI
of the brain and spinal axis revealed no cord compression,
but two brain metastases in the left pre-central gyrus and
left corona radiata were identified (Figure 2A). Second line
therapy with nivolumab was initiated at that time. The
CNS lesions, as well as two new 2 mm brain lesions in
the right frontal pole and cerebellum identified at the time
of treatment, were treated with gamma knife radiosurgery
20 Gy to the 50% isodose line in July 2016, after initiation
of nivolumab.
Four months later in October 2016, the patient had a fall and
brain MRI revealed a new 5 mm left posterior parietal lesion and
a small subdural hematoma. He was initially planned for further
radiosurgery, however, he became symptomatic with right arm
weakness, and repeat imaging revealed hematoma expansion
causing mass effect on the right ventricle and midline shift,
increased size of a left post-central gyrus lesion and improvement
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DISCUSSION
Patients with mRCC have benefited from the paradigm shift
brought about with the use of immune checkpoint inhibitors.
However, patients with brain metastases are often excluded
from these trials unless they have stable or treated disease
(10, 15, 16). A subgroup analysis of patients from the phase 3
Checkmate 025 trial who continued nivolumab after progression
of disease showed median OS of 22.5 months, compared to 12.3
months in subjects who were not treated beyond progression of
disease (17). Although not the focus of the analysis, this cohort
included patients who progressed due to brain involvement. The
French expanded access trial, GETUG-AFU 26 (Nivoren), is a
prospective phase II trial evaluating the efficacy and safety of
nivolumab in patients with mRCC. Those with brain metastases
(with or without previous focal treatment, not requiring steroids;
ECOG at least 2) were followed prospectively for intracranial
response rate. Seventy six (10.4%) subjects had brain metastases,
39 had not received focal treatment (cohort A), 34 had prior
focal treatment (cohort B), and 3 did not undergo treatment due
to performance status. Median follow up was 23.6 (95% CI =
18.1–24.6) months and 20.2 (95% CI = 16.3–22.9) months and
median duration of treatment was 4.9 (range: 0.5–24.2) months
and 4.5 (range 0.5–22.3) months for cohort A and B, respectively.
Median intracranial PFS was 2.7 months (95% CI = 2.3–4.6)
in cohort A and 4.8 months (95% CI = 3.0–8.0) in cohort B.
Prior focal brain therapy, as in cohort B, decreased the risk of
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FIGURE 1 | Timeline.

intracranial progression at a hazard ratio of 0.49 (95% CI = 0.26–
0.92). This study highlights the role of focal treatment of brain
metastases and notes that only four patients in cohort A achieved
objective intracranial response. Despite the favorable intracranial
PFS and lower incidence of symptoms due to brain metastases
among cohort B (32% in cohort B, 49% in cohort A, there was
no significant difference in 12-month overall survival (66.7% [CI
= 49.6–79.1) cohort A and 58.8% [CI = 40.6–73.2] cohort B)
(18, 19). The Italian expanded-access study consisted of patients
who were treated with Nivolumab for a median of 7.2 months
and included 32 (8.2%) patients with brain metastases that did
not require steroids or radiotherapy. The median PFS was 4.4
months (95% CI = 3.7–6.2), ORR was 23.1 and 36.2% of patients
had progressive disease. Overall survival at 6 and 12 months was
87 and 66.8% respectively, with median OS not reached at the
time of analysis. Treatment-related adverse events were similar
between the brain-metastatic patients and the overall population,
but grade 3–4 toxicities were more common among those with
brain metastases (12 vs. 7%) (20). These trials suggest improved
outcome for brain metastatic patients with acceptable toxicity
profiles. Indeed, the checkpoint 025 trial reported greater adverse
events for patients treated with everolimus than with nivolumab
(88%, compared with 79%) (10).
RCC has historically been considered a radioresistant tumor
and the role of radiation has been limited to the palliative setting
(21). Radioresistance was demonstrated in vitro in a 1995 metaanalysis in which RCC was found to have the highest survival
among 694 human cell lines after irradiation to a dose of 2 Gy
(13). The mechanism of resistance was proposed in 2005 and
highlighted the role of the HIF-1 pathway (22). A feature of
RCC is its loss of function mutation/methylation in the von
Hippel-Lindau (VHL) tumor suppressor gene. This results in
high levels of HIF-1α expression and upregulation of VEGF
and downstream proangiogenic factors that protect epithelial
cells and induce radioresistance. Clinical data seemed to uphold
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this concept. Two prospective studies in the 1970s investigated
neoadjuvant RT followed by nephrectomy vs. nephrectomy
alone in the non-metastatic setting failed to improve in 5-year
survival (23, 24). Studies of adjuvant RT by Kjaer et al. (25)
and Finney (26) similarly failed to improve survival and in
fact, the 1973 study was concerning for a significant number of
patient deaths (19.6%), in part due to radiation-induced liver
damage. In contrast, data from Haimovitz-Friedman et al. (27)
indicated that fractions larger than 8 Gy overcame the HIF-1
mediated resistance mechanism. These higher doses activate the
cell surface sphingomyelin pathway to produce ceramide and
induce apoptosis, providing an alternative pathway of cell death.
This was first supported in human data by a Phase I doseescalation study by Greco et al. (28) and a retrospective analysis
by Vogelbaum et al. (29) both demonstrating good locoregional
control and a dose-response (14).
Results from the first prospective trial to investigate
the combination of multi-site SBRT in combination with
pembrolizumab was reported at the 2018 ASCO-SITC Clinical
Immuno-Oncology Symposium. This is a Phase I clinical trial
studying the safety of SBRT and pembrolizumab in adults with
advanced solid tumors who have progressed on standard of
care treatment. Patients with active metastatic CNS disease were
excluded from the trial. Seventy-six subjects underwent SBRT
to up to four sites followed by pembrolizumab within 7 days
of the final radiation treatment. Most patients (94.5%) received
SBRT to two sites. Of the 76 subjects studied, only 1 case of RCC
was included. Median follow up was 5.5 months. Six grade 3
toxicities were observed, including three cases of pneumonitis,
two cases of colitis, and one case of hepatic failure. The ORR
was 13.2%, significantly greater in irradiated than non-irradiated
lesions (mean tumor diameter change 21.7% vs. 1.7%). Abscopal
effect, which is immune-mediated tumor response outside of
the radiation field, was observed in 13.5% of patients and was
defined as a 30% reduction in the aggregate sum of nonirradiated
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FIGURE 2 | (A) Pre-treatment MRI, coronal, and axial views, (B) post-SRS and immunotherapy MRI, (C) pre-treatment CT, coronal view, and (D) post-treatment CT.

participants were recruited and underwent SBRT to 1–2 sites
between the first and second cycles of nivolumab-ipilimumab.
Median follow up was 24 months. ORR was 56%, median PFS
8.21 months, and 1-year PFS rate 36%. The median OS and
duration of response had not been reached. Grade 3–4 toxicities
were reported in 36% of subjects (32). These two trials differed
not only in single vs. dual immunotherapy regimens, but also
in the radiation regimen. The RADVAX trial treated with SBRT
to a dose of 50 Gy in five fractions, while the NIVES trial
treated to a dose of 10 Gy in three fractions. It is not clear
whether the favorable results from the RADVAX trial are due
to the combination of nivolumab and ipilimumab, or more
optimal dosing of SBRT. An interim analysis of CheckMate 920
features safety and efficacy results for the cohort of patients
with brain metastases. Subjects who were previously untreated,
had asymptomatic brain metastases not requiring steroids or
radiation, and had a Karnofsky performance score of at least
70% were treated with nivolumab (3 mg/kg) and ipilumumab
(1 mg/kg) every 3 weeks for four doses followed by nivolumab

lesions. A similar reduction in any single nonirradiated site was
observed in 26.9% of patients (30). Two phase II trials evaluating
the combination of immunotherapy and SBRT in mRCC were
presented at the 2020 ASCO Genitourinary Cancers Symposium.
The NIVES trial recruited 69 immunotherapy-naive patients with
disease progression following at least two lines of anti-angiogenic
therapy. Patients received SBRT 7 days following the first infusion
of nivolumab and were continued on immunotherapy until
disease progression or toxicity. The most common sites of SBRT
were lung (37.7%), lymph nodes (11.6%), and bone (11.6%).
At median follow up of 15 months, ORR was 17.4%, CR 1.4%,
and disease control rate of 58%. Progression-free survival was
4.1 months, median OS was 22.07 months, and 1-year PFS and
OS rates were 32.6 and 73.4%, respectively. Grade 3–4 toxicities
were observed in 24.6% of patients and none of these occurred
within the radiation field (31). RADVAX RCC evaluated the
combination of nivolumab and ipilimumab with SBRT, with
most patients having previously undergone nephrectomy (68%).
The most common site for SBRT was lung (56%). Twenty-five
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480 mg every 4 weeks until disease progression or unacceptable
toxicity for up to 2 years. Twenty-eight patients were enrolled
with a median follow up of 6.47 months and analyzed for
the primary endpoint of high-grade immune-mediated adverse
events and secondary endpoints of progression free survival and
objective response rate, with exploratory endpoints of safety
analysis and overall survival. ORR was 28.6% (95% CI = 13.2–
48.7), median PFS 9 months (CI = 2.9 – not estimable), and
median OS had not been reached. There were six cases of grade
3–4 immune-mediated adverse events within 100 days of the last
dose of immunotherapy. These data suggest that there may be a
beneficial effect of SBRT which was reflected in results from the
RADVAX trial; however, long term follow up and randomized
data are required.
Further study is warranted, and future trials are underway.
The CYTOSHRINK trial is a Phase II randomized trial that
will include patients with advanced RCC who decline or are
unsuitable for cytoreductive nephrectomy. Subjects will be
randomized 2:1 to received ipilimumab or nivolumab plus SBRT
(30–40 Gy in five fractions) to the primary kidney lesion vs.
immunotherapy alone. The primary endpoint is the hazard
ratio for PFS, and secondary endpoints are safety, OS, ORR,
and health-related quality of life (NCT04090710) (33). There
are several more ongoing phase I/II trials testing the use of
stereotactic radiotherapy in combination with immunotherapy:
NCT02864615 (SBRT in mRCC treated with targeted or
immunotherapy), NCT02599779 (pembrolizumab + SBRT in
TKI-refractory mRCC), NCT02781506 (nivolumab + SAbR in
mRCC) (14) whose results will provide more insight into the
effectiveness of such regimens for patients with RCC.
The combination of immune checkpoint inhibitors and
radiation therapy may offer a pathway for achieving durable
clinical response through the abscopal effect. Physiologic
mechanisms responsible for the abscopal effect have been
proposed primarily utilizing non-small-cell-lung-cancer
(NSCLC) and melanoma as models. Twyman-Saint Victor
et al. (9) utilized a B16-F10 melanoma mouse model with
bilateral flank tumors and treated them with radiation to one
tumor, anti-CTLA4 antibodies, or both treatments concurrently.
The response rate in the concurrent treatment arm was 17%,
consistent with a human phase I clinical trial in patients with
metastatic melanoma, as reported by the same group. The top
predictor of resistance was the CD8+ /Treg ratio, which failed
to increase in resistant tumors but did increase in sensitive
tumors. The mechanism of resistance was not mediated by
factors contributing to radiation resistance, but rather factors
that blunt the expansion of CD8 T cells. Among these, the most
prevalent upregulated genes in resistant tumors were PD-L1
and interferon-stimulated genes. Elimination of PD-L1 using
CRISPR restored response to radiation and CTLA-4 blockade
and increased survival from 0 to 60%. Elevated levels of PD-L1
have been found to contribute to T-cell exhaustion. The addition
of PD-1 or PD-L1 blockade to radiation and anti-CTLA4
in the mouse models increased complete response rates to
80% and was strongly correlated with reversal of exhaustion
of CD8 T cells as well as an increase in the CD8/Treg ratio.
Additionally, assessment of T-cell receptors (TCR) revealed
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that irradiated tumors displayed increased diversity of TCR
clonotypes compared to unirradiated tumors. TCR clonotype
expansion was demonstrated in humans with NSCLC in a
prospective study of the combination of radiation and CTLA-4
blockade (34). The study included patients who progressed after
at least one prior treatment. Forty-one percent of patients on this
trial had pre-existing brain metastases controlled by surgery or
radiation. Patients received radiation to one metastasis and were
treated with concurrent ipilimumab. The objective response
rate was 33% in evaluable patients, with two patients achieving
complete response. In contrast to the melanoma mouse model,
in this study of human NSCLC neither PD-1 expression in
pretreatment tumor nor CD8 T cell infiltration was associated
with response. In addition, there was no evidence that PD-1+ T
cell exhaustion was a factor in response. Instead, EGFR mutation,
which is associated with poor response to PD-1/PD-L1 blockade
(35), was significantly higher in patients with progressive disease
than those with stable disease or partial/complete response.
Similar to the melanoma mouse model, peripheral blood TCR
clonotype diversity was associated with response, and had the
highest predictive value. Ongoing clinical trials studying the
abscopal effect in RCC include NCT02334709 (SBRT + TKI in
mRCC) and NCT03469713 (NIVES trial).
Here, we have presented a case of RCC with brain metastases
treated successfully with radiation and immunotherapy. The
patient continues to follow in clinic with stable imaging and
remains off treatment for over 2 years. His survival currently
exceeds expectations based on the available data and historical
averages. While anecdotal, this case is impressive and shows
long term control of brain metastatic RCC, as this patient has
remained off treatment, suggesting a robust treatment-induced
immune response. While limited in the tissue correlatives,
given the patient refused subsequent biopsies, his clinical
course compared to patients treated with immunotherapy alone
perhaps suggests some contribution of radiation. As mentioned,
additional formal clinical study of the abscopal effect in mRCC is
ongoing. Future avenues for research may investigate the optimal
sequencing of immunotherapy and SBRT in patients with mRCC,
the appropriate combinations and duration of treatment with
immunotherapeutic agents, and broader inclusion of patients
with CNS disease.
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